Domar

Quick links to important sections

Domar

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Domar

Property Description
Active ingredient Pinazepam
Form Oral solid forms (tablets/capsules)
Pharmacological class Benzodiazepine / Anxiolytic
General purpose Relief of anxiety and nervous tension
Origin Synthetic derivative

What Type of Medicine is Domar (Pinazepam)?

Domar is the medicine containing the single active ingredient Pinazepam, which is classified as a synthetic benzodiazepine derivative used primarily to relieve symptoms of anxiety. Pinazepam belongs to the general pharmacological grouping of psycholeptics and is specifically categorized as an anxiolytic, meaning its main action is directed toward alleviating nervous tension. As a synthetic compound, it is manufactured as a single-ingredient product intended for systemic effect.

The Pinazepam molecule is a derivative of the 1,4-benzodiazepin-2-one chemical structure, which defines the core identity of the benzodiazepine class. Its general function, clinically recognized for its specific anxiolytic profile, is to modulate nerve activity to promote calmness. Domar is typically delivered as a prescription-only medicine in oral solid forms such as tablets or capsules, utilizing the oral route of administration.


Pinazepam: Composition and General Therapeutic Purpose

The medicine's composition consists exclusively of the active substance Pinazepam, combined with standard solid pharmaceutical excipients necessary for manufacturing the oral form. The general therapeutic purpose of this composition is rooted in its class action, aiming to provide fundamental relief from nervous tension and anxiety.

The classification as an anxiolytic means the drug's general benefit is to manage the symptoms of generalized anxiety and emotional distress, such as chronic worrying or restlessness. A review of its properties concluded that Pinazepam acts as an effective anxiolytic agent, confirming that the medicine helps to reduce feelings of worry and restlessness.


The Unique Prodrug Mechanism of Pinazepam

Pinazepam is chemically distinct due to the presence of a propargyl group in its structure. This characteristic means Pinazepam functions as a prodrug, a substance that is largely inactive upon ingestion and must be metabolized by the body's liver to become fully effective. The body converts Pinazepam into the primary active compound, nordazepam (also known as N-desmethyldiazepam), which then carries out the therapeutic effect to modulate nerve signals. This unique metabolic process is crucial for the drug’s sustained systemic action on the brain, distinguishing its pharmacokinetic profile from many other short-acting benzodiazepine analogues.

Regulatory References

  1. Pinazepam (PIM 679) - INCHEM

What side effects are possible with Domar?

Possible Side Effects and Safety Information

The official safety profile for Domar (Pinazepam) primarily involves effects on the central nervous system, as documented in government regulatory sources. Adverse reactions are classified by frequency and system-organ class.

Common side effects resulting from Nervous System Disorders include somnolence (drowsiness), sedation, dizziness, and impaired coordination such as ataxia (unsteadiness). These effects are generally expected at the start of treatment and may lessen as the body adjusts.

The use of Pinazepam is associated with a high-level safety warning regarding dependence and withdrawal. Regular use can lead to physical and psychological dependence, and abrupt termination of treatment may result in a severe withdrawal syndrome, including life-threatening seizures.

A serious adverse reaction documented for the class is the increased risk of profound sedation and respiratory depression, leading to coma and death, particularly when Pinazepam is used concurrently with other central nervous system depressants like opioids. Furthermore, the label notes uncommon paradoxical reactions that may include agitation or aggressiveness.

Specific Safety Constraints exist for certain patient groups. Pinazepam is contraindicated in patients with conditions like Myasthenia gravis, sleep apnoea syndrome, severe respiratory insufficiency, and severe hepatic insufficiency. Older adults are also noted as being more susceptible to the medicine's CNS depressant actions, increasing the risk of falls.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Domar (Pinazepam) define the overdose profile primarily by its effect on the Central Nervous System (CNS). Documented manifestations of over-ingestion typically range from mild symptoms like drowsiness (somnolence), confusion, lethargy, and slurred speech to signs of impaired motor control, such as ataxia (uncoordinated movement) and hypotonia (decreased muscle tone).

Overdose severity is dose-related, but the risk of life-threatening outcomes increases significantly with higher doses or with co-ingestion of other CNS depressants. The most serious officially documented outcomes are profound coma and respiratory depression. Regulatory guidance explicitly states that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately if symptoms involve loss of consciousness, shallow breathing, or if the individual is unarousable.

The primary official management approach is symptomatic and supportive treatment, requiring close clinical observation and continuous monitoring of vital signs. While the specific antagonist flumazenil is noted in regulatory texts as a potential reversal agent, its use is often cautioned against or not routinely recommended due to the risk of adverse effects. Regulatory notes also specify that elderly patients and those with impaired liver function may be more susceptible to the depressant actions and accumulation risks of overdose.

Therapeutic Uses of Domar

What Domar Treats: Main Uses and Benefits

Domar (Domperidone) is commonly used to help with symptoms related to physical discomfort in the upper gastrointestinal tract. The medicine is relevant in contexts marked by increased discomfort or tension, specifically addressing acute nausea and vomiting.

It may be part of symptomatic management in clinical settings where patients experience symptoms that become more disruptive during flare-ups, such as nausea caused by certain treatments for Parkinson’s disease. It is used in situations involving certain distressing symptoms, including feelings of fullness, bloating, and discomfort often associated with slow digestion (like in gastroparesis). This short-term symptomatic assistance is generally used to help address symptom clusters that may become intense or disruptive, and provides support that helps ease the overall symptom burden.


Quick Fact: Support for Acute Nausea Symptoms Domperidone is commonly used to help with symptoms that appear suddenly, offering symptomatic relief that assists with functional stability during symptomatic phases.


Regulatory References

  1. GOV.UK Medicines and Healthcare products Regulatory Agency Guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Domar (Pinazepam)?

Official regulatory documents define strict eligibility criteria for the use of Domar, which contains the active ingredient Pinazepam. Use is generally established for adults requiring short-term relief from anxiety. However, several populations are absolutely contraindicated (must not use) or require conditional use.


Absolute Prohibitions (Contraindications)

According to regulatory labeling, Domar is contraindicated in patients with:

  • Severe respiratory insufficiency, including acute pulmonary failure and sleep apnoea syndrome.
  • Severe hepatic insufficiency (severe liver failure), due to the risk of encephalopathy.
  • Myasthenia gravis (a severe neuromuscular disorder).
  • Known hypersensitivity to Pinazepam or any other benzodiazepine.

Eligibility Restrictions

Population Group Regulatory Status
Pediatric Patients (Children/Adolescents) Not recommended for routine anxiety treatment.
Elderly Patients (Geriatric) Conditional Use; requires lower starting doses and close monitoring.
Pregnancy/Lactation Not recommended or Not advised (drug passes into breast milk).
Renal Impairment Conditional Use; requires monitoring and dose adjustment.
Substance Abuse History Avoided or used with extreme caution due to high risk of dependence.

These official classifications determine who can and cannot use the medicine, based on physiological and developmental constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Pinazepam (Domar) is structured around patterns documented in government regulatory sources, primarily concerning combined effects on the central nervous system (CNS) and alterations in drug exposure.

Interaction Scope

Category Official Regulatory Statement
Pharmacodynamic Risk Co-administration with Opioids and other CNS Depressants (including Alcohol, Antipsychotics, and Sedative Hypnotics) results in an additive depressant effect, documented to increase the risk of severe respiratory depression, coma, and death.
Metabolic Interactions Pharmacokinetic alteration via hepatic enzymes (CYP) is documented. Cimetidine and Erythromycin are enzyme inhibitors that can increase the plasma concentration of the active drug. Rifampicin and Phenytoin are enzyme inducers that may decrease the drug's systemic exposure.
Substance Interactions Alcohol co-administration is strictly restricted by regulatory warnings due to its severe additive CNS depressant effects. Herbal products like St. John's Wort may also alter metabolism or enhance CNS depression.
Population Note Regulatory documentation notes that Elderly Patients are more susceptible to the severe sedative effects of co-administered CNS depressants, which increases the risk of falls.

Official Interaction Structure

The regulatory profile defines the highest risk interaction as the combination of Pinazepam with Opioids, which is subject to a strong regulatory warning concerning life-threatening risks. Other interaction statements identify substances that either alter the drug's clearance (e.g., enzyme inhibitors/inducers) or oppose its effect (e.g., Caffeine), as documented in prescribing information.

Mechanism of Action

D2 Receptor Antagonism and Central Pathway Modulation

Domar acts as a competitive antagonist at the D2 subtype of dopamine receptors, primarily within the central nervous system. This molecular interaction physically occupies the binding site, thereby preventing the endogenous neurotransmitter dopamine from activating the receptor. This blockade initiates a mechanistic cascade in dopaminergic circuits, leading to the reduction of signaling in hyperactive pathways, such as the mesolimbic system. The central action of blocking D2 receptors modifies the early molecular steps of the Gi/o-protein signaling cascade, resulting in a functional shift in pathway activity within targeted neural circuits.


Physiological Consequences of Dopamine Signal Blocking

Blocking D2 receptor signaling produces specific, non-indicational physiological changes across multiple systems. This includes the potential for altered motor control due to action in the nigrostriatal pathway. Furthermore, antagonism in the tuberohypophyseal pathway causes a resultant change in endocrine regulation; the removal of the inhibitory tone on the pituitary gland leads directly to elevated prolactin levels. These physiological adjustments are direct consequences of the drug's D2 antagonism.

Dosage and Administration Information

How to Use Domar — Official Administration Guidelines

The correct use of Domar follows established protocols, focusing on precise timing, dosing, and procedural steps. The medicine is administered orally (by mouth) and is restricted for use in adolescents (12 years and older) and adults weighing at least 35 kg.


Administration Protocol

Procedural Step Official Requirement
Timing Relative to Meals Must be taken 15 to 30 minutes before a meal.
Tablet Procedure Tablets should be swallowed whole with a sufficient amount of liquid.
Dosing Frequency The maximum frequency is up to three times daily.
Dosing Interval A minimum of 8 hours must pass between each dose.

Official Dosing Rules

The official instructions define both the single dose limit and the overall daily limit to ensure correct use. The maximum single dose is typically 10 mg, and the total amount taken in a 24-hour period must not exceed 30 mg.

If a dose is missed: The official instruction is to skip the missed dose entirely and take the next scheduled dose at the usual time. Do not take a double dose to make up for a forgotten dose, as this could exceed the established safety limits.

These guidelines establish a mandatory daily protocol that governs when the medicine is taken, how much is taken, and the minimum time required between doses, ensuring standardized use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Domar (Pinazepam)

Research Evidence for Symptomatic Relief of Anxiety

This section will summarize the core clinical evaluation for Pinazepam, outlining the types of controlled and open-label trials conducted for the relief of anxiety symptoms and nervous tension, and detailing the high-level outcomes measured by researchers. Research for Domar has examined short-term symptom changes in adults experiencing anxiety, using Controlled Clinical Trials and Open Clinical Trials to investigate how symptoms evolved during defined time intervals.

Studies were conducted to assess how symptoms changed, with researchers examining outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. The trials monitored factors such as the intensity of nervous tension and measured functional outcomes, including changes in activity level. The findings from these studies describe patterns observed in the studied populations, reporting various measurements of changes in anxiety severity scores.

Focus of Early Comparative Clinical Trials

Much of the evidence for Pinazepam stems from comparative studies that were relevant in trials assessing short-term or episodic symptom patterns. These older trials typically compared Pinazepam to other agents within the benzodiazepine class. The results from these trials highlight changes measured during the study period in specific research contexts.

Pharmacological and Physiological Studies

Pinazepam was evaluated in pharmacokinetic studies, mainly involving healthy volunteers. These studies established that the medicine functions as a prodrug, meaning it converts into the primary active substance, Nordazepam, in the body. The research provided data to establish the drug's metabolic profile.

Further studies examined outcomes related to systemic function by monitoring physiological changes. Data from pharmacological reviews described the drug’s properties, noting observed measurements of sedation and motor performance. Findings describe patient-reported experiences related to these physiological changes.

Key Limitations and Research Gaps

Long-term effects are not fully established, and the majority of the published clinical studies for Pinazepam have limited follow-up durations. The research provides insight into short-term changes, but the long-term patterns of symptom evolution are not well characterized. Research has documented several key limitations and research gaps for Pinazepam, including the fact that many of the original efficacy studies are older and may not fully align with modern trial standards.

Key Studies & References

  1. WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification, N05BA14 (Pinazepam)
  2. INCHEM International Programme on Chemical Safety (IPCS) Pinazepam (PIM 679)

Frequently Asked Questions (FAQ)

Common questions about Domar (FAQ)

Q: How does Domar relieve anxiety?

According to official product information, Domar contains the active ingredient Pinazepam, which belongs to the class of medicines known as benzodiazepines. This drug acts as a central nervous system depressant, which means it reduces activity in the brain. This action is associated with the drug's purpose: alleviating symptoms of anxiety and nervous tension.

Q: What is the longest I can take Domar?

Regulatory documents generally advise that benzodiazepines, as a class, are typically recommended for short-term use. To minimize the risk of dependence and withdrawal, many official guidelines suggest a limited duration of use, often less than four weeks, to minimize risk of dependence.

Q: Are there any food restrictions when taking Domar?

Official guidelines for administering Domar require it to be taken 15 to 30 minutes before a meal. However, regulatory product information does not generally list specific restrictions on the types of food or dietary components that must be avoided.

Q: Does Domar have a potential for abuse?

Yes, regulatory authorities have designated Domar as a controlled substance (DEA Schedule IV). This classification reflects its potential for problematic use, addiction, and physical or psychological dependence. Official safety warnings stress the importance of using this medicine exactly as prescribed.

Q: How should I stop taking Domar?

Regulatory guidance advises against stopping this medicine abruptly. Sudden discontinuation is associated with a risk of severe withdrawal symptoms, including the potential for seizures. Official product information emphasizes that discontinuation should involve a gradual dosage reduction plan, rather than stopping suddenly.

How should Domar be stored and disposed of?

How to Store and Dispose of Domar (Domperidone)

Official regulatory documents require Domar to be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must be stored in a tightly closed container and kept protected from both light and moisture to maintain its stability. Do not refrigerate or freeze certain formulations, such as suppositories.

Always ensure Domar is stored out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired medication must be handled in accordance with local regulations and requirements. It must not be disposed of via household wastewater unless explicitly advised by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Domar found in:

A-Z Index: